There's been a lot of talk about using artificial intelligence in drug development over the past year. Now, it’s a lot closer ...
As bispecifics, ADCs, protein degraders, and AI-designed mini-proteins move into the clinic, discovery teams face a new ...
Tessera will receive $150 million in upfront cash and equity investment from Regeneron and be eligible for up to $125 million in milestone payments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback